Welcome to our dedicated page for VLNCF news (Ticker: VLNCF), a resource for investors and traders seeking the latest updates and insights on VLNCF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VLNCF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VLNCF's position in the market.
The Valens Company has announced a white label partnership with Fire & Flower Holdings Corp to manufacture and distribute Revity CBD oil. This collaboration aims to expand Valens' wellness-focused product line across Ontario, Manitoba, and Saskatchewan, with potential expansion to other regions. Valens will utilize its proprietary processing methods to enhance product quality. Both companies expressed confidence in meeting the evolving needs of the Canadian CBD market through this strategic partnership.
The Valens Company (OTCQX: VLNCF) announced a white label partnership with Fire & Flower Holdings Corp (OTCQX: FFLWF) on September 9, 2021. Valens will produce and distribute Revity CBD oil for Fire & Flower, targeting markets in Ontario, Manitoba, and Saskatchewan, with potential expansion plans. This collaboration emphasizes Valens' focus on wellness products and enhances its manufacturing portfolio. Both companies express confidence in the partnership, citing Valens' manufacturing excellence and Fire & Flower's retail capabilities in the rapidly evolving Canadian cannabis market.
The Valens Company (OTCQX: VLNCF) has announced a strategic partnership with Epsilon Healthcare to access Epsilon's Good Manufacturing Practices (GMP) facility in Australia. This partnership aims to enhance Valens's international expansion by allowing access to GMP markets, including Latin America, Europe, the UK, and Asia-Pacific. Valens will handle all operational costs of the Southport Facility and gain preferential access to 85% of its capacity for five years, with an option to extend. This marks Valens's first GMP manufactured products in Australia.
The Valens Company has completed the acquisition of Verse Cannabis, positioning itself as a leading cannabis producer in Canada. This acquisition, along with the agreement to acquire Citizen Stash, increases Valens' market share with over 220 listings across 7 provinces. Verse is known for its innovative, value-focused cannabis products, and the acquisition is projected to be accretive to Valens in 2021 and 2022. The company aims to leverage Verse's brand to enhance its product offerings and maximize shareholder value.
Valens has announced a strategic acquisition of Citizen Stash Cannabis Corp. valued at approximately $54.3 million. This move aims to strengthen Valens' entry into the $2.7 billion flower-based market and enhance its market share with the #1 flower brand, Citizen Stash, known for its premium pricing over $13.00/gram. The acquisition is expected to be accretive in 2021 and 2022, driven by significant revenue and cost synergies. Valens will use an asset-light model with craft contract growers, reducing operational risks while expanding its product offerings across various Canadian provinces.
The Valens Company (TSX: VLNS) has announced a distribution agreement with Tele Marche Co., Ltd. to offer its Green Roads CBD products online in Japan. This collaboration aims to leverage Green Roads' successful e-commerce strategy, which averages around 9,000 orders monthly in the US. The online store will provide a wide range of CBD products, including tinctures, gummies, and pet products, along with educational resources for consumers. The expansion into Japan is viewed as a significant growth opportunity for Valens, which is increasing its international distribution footprint.
The Valens Company has received authorization from the Autorité des marchés publics (AMP) to contract with public bodies in Quebec. This authorization allows Valens to become a registered vendor in Quebec, which represents a significant opportunity as it is the third-largest cannabis market in Canada, accounting for approximately 17% of national cannabis sales and 22% of the population. This marks an important step for Valens in expanding its domestic distribution network, with Quebec being the seventh province added, enhancing their strategic market presence.
The Valens Company (OTCQX: VLNCF) announced upgrades to its Valens Labs testing facility to meet international cannabis testing standards. These improvements facilitate testing for over 300 pesticides, enhancing the lab's capabilities in anticipation of growing global demand. The upgrades ensure compliance with international analytics and testing, supporting customers' export goals. Valens Labs is now positioned as a leading cannabis testing center in Canada, maintaining ISO/IEC 17025:2017 accreditation, and aiming to expand its market reach internationally.
The Valens Company has launched three new cannabis products in collaboration with Verse Cannabis, including its first cannabis-infused beverage, Rapid Tropical Rush. This beverage contains 10 mg of THC and 10 mg of CBD, targeting Canadian markets like Alberta and British Columbia. Additionally, two new vape cartridges are available: Mango Nectar and Live Terp Guava x BC Blueberry. All products aim to diversify Verse's portfolio, enhancing consumer options in the cannabis market.
